Abstract:The aim of interventions over the respiratory microbiome in COPD is to preserve the original microbial flora, focusing in taxa with a demonstrated impact on the prognosis of the disease. Inhaled therapy is the main treatment for COPD, and chronic corticosteroid use is recommended for patients with frequent exacerbations. This therapy, however, increases both the bronchial microbial load and the abundance of potentially pathogenic bacteria in patients with low peripheral eosinophil counts, and to minimize its use in patients without peripheral eosinophilia, when possible, may avoid increases in bacterial loads of microorganisms as Haemophilus influenzae and Streptococcus pneumoniae. In exacerbations antibiotics determine a decrease in the microbial diversity, a change that persists during stability periods in frequent exacerbators. High-diversity bronchial microbiomes are enriched in non-dominant genera and determine low exacerbation frequencies and survival improvement. Limiting the antibiotic use to the treatment of exacerbations which would clearly benefit would favor the diversity of the respiratory microbiome and may have a positive impact on quality of life and survival. Oral antiseptics have shown and effect on the bronchial microbiome that was associated with improvements in quality of life, and the gut microbiome may be also modified through the oral administration of probiotics or prebiotics, that potentially may determine decreases in lung inflammation and bronchial hyperreactivity. High fiber diets also favor the production of anti-inflammatory molecules by the digestive flora, which would reach the respiratory system through the bloodstream. Interventional approaches favoring the preservation of the respiratory microbiome in COPD need first to select accurately the patients who would benefit from long-term inhaled corticosteroids and antibiotic treatments during exacerbations, under the hypothesis that keeping a respiratory microbiome close to the healthy subject would favor the respiratory health. Additionally, high fiber diets may be able to modify the gut microbiome and influence the respiratory system through the gut-lung axis. Therapeutic approaches targeting the microbiome to improve COPD, however, still require clinical validation and the identification of patient subtypes who would benefit the most with their use.

Targeting respiratory microbiomes in COPD and bronchiectasis

Airway microbiome-immune crosstalk in chronic obstructive pulmonary disease

Lung microbiome, gut–lung axis and chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease and the airway microbiome: A review for clinicians

The Microbiome in COPD: Emerging Potential for Microbiome-Targeted Interventions

The association between the respiratory tract microbiome and clinical outcomes in patients with COPD

The Human Respiratory Microbiome: Current Understandings and Future Directions

Infection and the microbiome in bronchiectasis

Impact of Lung Microbiota on COPD

Lung microbiota and potential treatment of respiratory diseases

Interactions between the lung microbiome and host immunity in chronic obstructive pulmonary disease

The Lung Microbiome

The microbiome in bronchiectasis

Microbiome effects on immunity, health and disease in the lung

Gut Microbiome as a Possible Cause of Occurrence and Therapeutic Target in Chronic Obstructive Pulmonary Disease

Role of the Lung Microbiome in the Pathogenesis of Chronic Obstructive Pulmonary Disease

Gut microbiome a promising target for management of respiratory diseases

Role of the lung microbiome in the pathogenesis of chronic obstructive pulmonary disease.

A clinicians' review of the respiratory microbiome

Lung microbiome: new insights into the pathogenesis of respiratory diseases

The airway microbiome in cystic fibrosis and implications for treatment